Dr Jairath discusses the phase 2B study results of icotrokinra, a novel, oral interleukin-23 peptide, for the treatment of moderately to severely active ulcerative colitis, which were presented at the ACG 2025 Scientific Meeting.
Dr Jairath discusses the phase 2B study results of icotrokinra, a novel, oral interleukin-23 peptide, for the treatment of moderately to severely active ulcerative colitis, which were presented at the ACG 2025 Scientific Meeting.
Dr Jairath discusses the phase...